Abstract 1214P
Background
HRR gene alterations are enriched in prostate cancer (PC) and are associated with sensitivity to PARP inhibitors. Homozygous deletion (HD), which accounts for up to 15% of HRR gene alterations in PC, is an important type of pathogenic alteration. However, the reliable detection of HD is technically challenging. Here we introduced a novel machine learning based method for HD detection in formalin-fixed paraffin-embedded (FFPE) PC tissues.
Methods
HD/non-HD simulation events (∼30000) of varying tumor cellularity and fragment size were constructed using the sequencing data of matched tumor and wild type cell lines tested by AmoyDx HRD Complete NGS panel. Seven artificial features were calculated based on genomic segment depth and minor allele frequency of single nucleotide polymorphisms, tumor cellularity and tumor ploidy. The feature data were fed into the xgboost with 10-StratifiedKFold to generate HD recognition model (training :validation datasets=7:3). Analytical performance was assessed with reference cell lines: specificity with wildtype cell lines, sensitivity with gradient HD-positive cell lines (tumor cellularity: 20%, 30%, 40%, 50%) with varying DNA input (30ng, 50ng, 100ng), reproducibility of intra- and inter-runs, and anti-interference against hemoglobin, triglycerides, xylene, paclitaxel, and ethanol. Clinical performance was evaluated using FFPE PC tissues.
Results
The trained HD model achieved 99.8% accuracy in the in silico validation dataset. Analytical validation demonstrated: 100% specificity; 100% sensitivity at gene level with 30% tumor cellularity and at exon level with 40% tumor cellularity with 100ng DNA input; 100% reproducibility; strong anti-interference capability with all HD events detected and no false positives. 132 FFPE PC tissues showed high consistency with a second validated NGS assay (PPA 100%, NPA 98.4%, OPA 98.5%).
Conclusions
A machine learning based method was successfully developed and adopted in multiple NGS assays to detect HD of HRR genes in PC tissues. It provides a reliable approach to effectively identify PC patients with HRR HD.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Janssen.
Disclosure
J. Wang, P. Cheng, W. Xu, Z. Huang, X. Chen, S. Liu, Y. Guo, W. Shi, S. Yang: Financial Interests, Personal, Full or part-time Employment: Amoy Diagnostics. X. Ye, U. Singh, K. Bell, K. Urtishak, L. Luo, X. Lyu, L. Zhou: Financial Interests, Institutional, Full or part-time Employment: Janssen Research & Development.
Resources from the same session
1807P - Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status
Presenter: Nobuaki Matsubara
Session: Poster session 14
1808P - Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m<sup>2</sup>) versus every 3 weeks (25 mg/m<sup>2</sup>) in the CABASTY phase III trial
Presenter: Stephane Oudard
Session: Poster session 14
1809P - Dynamics of plasma tumour DNA and copy number alterations in advanced metastatic castration-resistant prostate cancer (mCRPC) patients treated with cabazitaxel: A prospective biomarker trial
Presenter: Nicole Brighi
Session: Poster session 14
1810P - Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer
Presenter: Michael Morris
Session: Poster session 14
1811P - Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from a phase III (TALAPRO-2) study
Presenter: Andre Fay
Session: Poster session 14
1813P - Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results
Presenter: Andrew Laccetti
Session: Poster session 14
1814P - First real-life data on [177Lu]Lu-PSMA-617: Descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in early access in France
Presenter: Anne-Laure Giraudet
Session: Poster session 14
1815P - Emergent circulating tumor DNA (ctDNA) variants and ctDNA burden dynamics with potential associations with talazoparib antitumor activity in TALAPRO-1
Presenter: Elena Castro
Session: Poster session 14